BiotechTube

CLG561 + LFG316 + Sham injection

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy

Trial Timeline

Sep 25, 2015 → Dec 1, 2017

NCT ID
NCT02515942

About CLG561 + LFG316 + Sham injection

CLG561 + LFG316 + Sham injection is a phase 2 stage product being developed by Novartis for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02515942. Target conditions include Geographic Atrophy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02515942Phase 2Completed

Competing Products

20 competing products in Geographic Atrophy

See all competitors
ProductCompanyStageHype Score
avacincaptad pegolAstellas PharmaPhase 3
77
Avacincaptad PegolAstellas PharmaPhase 2/3
65
avacincaptad pegolAstellas PharmaApproved
85
Avacincaptad pegol (ACP)Astellas PharmaPre-clinical
23
Avacincaptad Pegol + ShamAstellas PharmaPhase 3
77
ABBV-6628 + SYFOVREAbbViePhase 1/2
41
FWY003 + PlaceboNovartisPhase 2
52
LFG316 + Sham + LFG316 Lower doseNovartisPhase 2
52
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
RO7669330 + Syfovre™ + Izervay™RochePhase 1
33
RO7303359RochePhase 1
33
SAR446597 + Sham ComparatorSanofiPhase 1/2
40
PozelimabRegeneron PharmaceuticalsPhase 1
32
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)Ionis PharmaceuticalsPhase 2
49
Tinlarebant + PlaceboBelite BioPhase 3
74
PegcetacoplanApellis PharmaceuticalsPre-clinical
18
APL-2 + APL-2Apellis PharmaceuticalsPhase 3
72
APL-2, PegcetacoplanApellis PharmaceuticalsPhase 3
72

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85